Montelukast vs Medroxyprogesterone: side-by-side comparison
Montelukast (Leukotriene receptor antagonist) and Medroxyprogesterone (Progestin) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Montelukast | Medroxyprogesterone |
|---|---|---|
| Therapeutic class | Leukotriene receptor antagonist | Progestin |
| CAS | 158966-92-8 | 520-85-4 |
| ATC | R03DC03 | G03DA02 |
| Molecular weight | 586.18 g/mol | 344.49 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Montelukast and Medroxyprogesterone share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Montelukast acts by a different mechanism than Medroxyprogesterone, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Montelukast: Montelukast selectively blocks the CysLT1 receptor, which mediates the action of leukotrienes C4, D4 and E4 — proinflammatory mediators released by mast cells and eosinophils in the airway. Medroxyprogesterone: MPA binds progesterone receptors and produces strong progestational effects: thickening cervical mucus, inhibiting ovulation, thinning the endometrium and reducing hot flashes.
Indications compared
Montelukast: Montelukast is approved in adults and children for the maintenance treatment of asthma, including exercise-induced bronchospasm, and for the treatment of seasonal and perennial allergic rhinitis when conventional therapy… Medroxyprogesterone: MPA is approved for amenorrhoea, abnormal uterine bleeding due to hormonal imbalance, prevention of endometrial hyperplasia in postmenopausal women receiving estrogen, and prevention of pregnancy (depot formulation).
Safety profile
Montelukast: Common adverse effects include headache, gastrointestinal symptoms and upper respiratory tract infection. Medroxyprogesterone: Common adverse effects of oral MPA include irregular bleeding, breast tenderness, mood changes, fluid retention and weight gain.
Frequently asked questions
Is Montelukast better than Medroxyprogesterone? ▾
Montelukast and Medroxyprogesterone are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Montelukast and Medroxyprogesterone be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Montelukast
Products with Medroxyprogesterone
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.